Oncocyte Publishes Study Demonstrating Predictive Potential

Data show that DetermaIO demonstrates superior accuracy compared to standard of care PD-L1 IHC for predicting a patient’s response to immunotherapy...

Related Keywords

Oncocyte Determa ,Neoadjuvant Immunochemotherapy ,Rob Seitz ,Bob Yedid ,Megan Kernan ,Exchange Commission ,Yale University ,Oncocyte Corporation ,Lifesci Advisors ,Oncocyte Corporation Nasdaq ,Baylor University ,Novel Immunomodulatory ,Gene Signature ,Predict Response ,Primary Triple Negative Breast ,Triple Negative Breast Cancer ,Immune Oncology ,Forward Looking ,Sci Advisors ,Nasdaq Ocx ,